TY - JOUR
T1 - Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants
AU - Gonzalo, Rosa M.
AU - Rodríguez, Dolores
AU - García-Sastre, Adolfo
AU - Rodríguez, Juan Ramón
AU - Palese, Peter
AU - Esteban, Mariano
N1 - Funding Information:
VV recombinants VV-Env-IIIB and VV-PYCS have been previously described [12, 26] . Recombinant VV-Env-MN expressing the entire env protein from HIV-1 strain MN was provided by the AIDS Research Reagent Program (NIH, Bethesda, D.C.) (Cat♯900). VV recombinants were grown in BSC-40 cells, and purified by binding in sucrose gradients as previously described [27] .
PY - 1999/2/26
Y1 - 1999/2/26
N2 - With the aim to determine if immunization with two different live recombinant viral vectors could lead to an enhancement of the cellular immune response to HIV-1 antigens, we have characterized the CD8+ T cell response elicited against the V3 loop epitope from HIV-1 env protein in Balb/c mice immunized with either: a recombinant influenza virus (Flu-Env) expressing the V3 loop epitope from HIV-1 strain IIIB, a vaccinia virus recombinant (VV- Env) expressing the complete HIV-1-IIIB env protein, or a combination of both. The CD8+ T cell response, measured by the ELISPOT assay, in animals primed with Flu-Env and boosted with VV-Env was 5 to 6 times higher than in animals inoculated with either Flu-Env or VV-Env alone. Similar results were obtained with recombinant viruses expressing the V3 loop epitope or the complete env protein, respectively, from the MN strain of HIV-1. Our results indicate that the use of two different live vectors for priming and boosting has a synergistic effect on the immune response against HIV-1, and could represent a novel vaccination strategy against AIDS.
AB - With the aim to determine if immunization with two different live recombinant viral vectors could lead to an enhancement of the cellular immune response to HIV-1 antigens, we have characterized the CD8+ T cell response elicited against the V3 loop epitope from HIV-1 env protein in Balb/c mice immunized with either: a recombinant influenza virus (Flu-Env) expressing the V3 loop epitope from HIV-1 strain IIIB, a vaccinia virus recombinant (VV- Env) expressing the complete HIV-1-IIIB env protein, or a combination of both. The CD8+ T cell response, measured by the ELISPOT assay, in animals primed with Flu-Env and boosted with VV-Env was 5 to 6 times higher than in animals inoculated with either Flu-Env or VV-Env alone. Similar results were obtained with recombinant viruses expressing the V3 loop epitope or the complete env protein, respectively, from the MN strain of HIV-1. Our results indicate that the use of two different live vectors for priming and boosting has a synergistic effect on the immune response against HIV-1, and could represent a novel vaccination strategy against AIDS.
KW - CD8 T cells
KW - HIV-1 env
KW - Influenza and vaccinia virus recombinants
UR - http://www.scopus.com/inward/record.url?scp=0344096503&partnerID=8YFLogxK
U2 - 10.1016/S0264-410X(98)00274-6
DO - 10.1016/S0264-410X(98)00274-6
M3 - Article
C2 - 10067695
AN - SCOPUS:0344096503
SN - 0264-410X
VL - 17
SP - 887
EP - 892
JO - Vaccine
JF - Vaccine
IS - 7-8
ER -